Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 Lutetium-177 Labeled Therapeutics: ¹⁷⁷Lu-PSMA is Set to Redefine Prostate Cancer Treatment.

× No keyword cloud information.

5 in total

1. Detection rate of PET/CT in patients with biochemical relapse of prostate cancer using [⁶⁸Ga]PSMA I&T and comparison with published data of [⁶⁸Ga]PSMA HBED-CC.

Authors: Christoph Berliner; Milena Tienken; Thorsten Frenzel; Yuske Kobayashi; Annabelle Helberg; Uve Kirchner; Susanne Klutmann; Dirk Beyersdorff; Lars Budäus; Hans-Jürgen Wester; Janos Mester; Peter Bannas
Journal: Eur J Nucl Med Mol Imaging Date: 2016-11-28 Impact factor: 9.236

2. Reconstructed SPECT images of ¹⁷⁷Lu homogeneous cylindrical phantom used for calibration and texture analysis.

Authors: Emilio Mezzenga; Filippo Piccinini; Emiliano Loi; Maria Luisa Belli; Anna Sarnelli
Journal: Sci Data Date: 2022-07-15 Impact factor: 8.501

3. Quantitative accuracy of 177Lu SPECT imaging for molecular radiotherapy.

Authors: Emilio Mezzenga; Vincenzo D'Errico; Marco D'Arienzo; Lidia Strigari; Koutla Panagiota; Federica Matteucci; Stefano Severi; Giovanni Paganelli; Andrew Fenwick; David Bianchini; Francesco Marcocci; Anna Sarnelli
Journal: PLoS One Date: 2017-08-14 Impact factor: 3.240

Review 4. Lutetium ¹⁷⁷ PSMA radionuclide therapy for men with prostate cancer: a review of the current literature and discussion of practical aspects of therapy.

Authors: Louise Emmett; Kathy Willowson; John Violet; Jane Shin; Ashley Blanksby; Jonathan Lee
Journal: J Med Radiat Sci Date: 2017-03

Review 5. Positron Emission Tomography-Based Response to Target and Immunotherapies in Oncology.

Authors: Maria Isabella Donegani; Giulia Ferrarazzo; Stefano Marra; Alberto Miceli; Stefano Raffa; Matteo Bauckneht; Silvia Morbelli
Journal: Medicina (Kaunas) Date: 2020-07-24 Impact factor: 2.430

5 in total

Lutetium-177 Labeled Therapeutics: ¹⁷⁷Lu-PSMA is Set to Redefine Prostate Cancer Treatment.

1. Detection rate of PET/CT in patients with biochemical relapse of prostate cancer using [68Ga]PSMA I&T and comparison with published data of [68Ga]PSMA HBED-CC.

2. Reconstructed SPECT images of 177Lu homogeneous cylindrical phantom used for calibration and texture analysis.

3. Quantitative accuracy of 177Lu SPECT imaging for molecular radiotherapy.

Review 4. Lutetium 177 PSMA radionuclide therapy for men with prostate cancer: a review of the current literature and discussion of practical aspects of therapy.

Review 5. Positron Emission Tomography-Based Response to Target and Immunotherapies in Oncology.

1. Detection rate of PET/CT in patients with biochemical relapse of prostate cancer using [⁶⁸Ga]PSMA I&T and comparison with published data of [⁶⁸Ga]PSMA HBED-CC.

2. Reconstructed SPECT images of ¹⁷⁷Lu homogeneous cylindrical phantom used for calibration and texture analysis.

Review 4. Lutetium ¹⁷⁷ PSMA radionuclide therapy for men with prostate cancer: a review of the current literature and discussion of practical aspects of therapy.